Molecular aspects of prostate cancer: Implications for future directions

International Braz J Urol

Volumn 29, Issue 5, 2003, Pages 401-410

  Gimba, Ethel Rodrigues Pereira ^a   Barcinski, Marcello A ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Carcinoma; Genomics; Micro array; Molecular markers; Prostatic neoplasms

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; GENE PRODUCT; OSTEOCALCIN; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CHROMOSOME; DISEASE ACTIVITY; DNA MICROARRAY; DNA SEQUENCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE THERAPY; GENETIC ANALYSIS; HUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

EID: 0345602785     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1677-55382003000500003     Document Type: Article

References (54)

1. Li PE, Nelson PS: Prostate cancer genomics. Curr Urol Rep. 2001; 2: 70-8.
2. Karan D, Lin MF, Johnsson SL, Batra SK: Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer. 2003; 103: 285-93.
3. Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, Devere White RW, Schroder FH, et al.: Future prospects in prostate cancer. Prostate. 1999; 40: 261-8.
4. Harding MA, Theodorescu D: Prostate tumor progression and prognosis: interplay of tumor and host factors. Urol Oncol. 2000; 5: 258-64.
5. Verhagen PCa, Tilanus MG, de Werger RA, van Moorselaar RJ, van d JG, Boon TA: Prognostic factors in localized prostate cancer with emphais application of molecular techniques. Eur Urol. 2002; 41: 363-71.
6. Brooks JD: Microarray analysis in prostate cancer research. Curr Opin Urol. 2002; 12: 395-9.
7. Lukes M, Uebam M, Zalesky M, Zachoval R, Heroucek J, Zdarsky E: Prostate-specific antigen: current status. Folia Biol. 2001; 47: 41-9.
8. Balk SP, Ko YJ, Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol. 2003; 21: 383-91.
9. Karazanashvili G, Abrahamsson PA: Prostate specific antigen and hunan glandular kallikrein 2 in the detection of prostate cancer. J Urol. 2003; 169: 445-57.
10. Grouse LH, Munson PJ, Nelson PS: Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology. 2001; 57 (4 Suppl 1): 154-9.
11. Ho SM, Lau KM: DNA microarrays in prostate cancer. Curr Urol Rep. 2002; 3: 53-60.
12. Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G: Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res. 2002; 62: 3308-14.
13. Dhahasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al.: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412: 822-6.
14. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al.: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002; 62: 4499-506.
15. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, et al.: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol. 2002; 160: 2169-80.
16. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al.: Gene expression correlates of clinical prostate behavior. Cancer Cell. 2002; 1: 203-9.
17. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S: HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002; 62: 6812-6.
18. Magee JA, Araki T, Patil S, Shrig T, True L, Humphrey PA, et al.: Expression profile reveals hepsin overexpression in prostate cancer. Cancer Research. 2001; 61: 5692-6.
19. McGarvey TW, Nguyen T, Puthiyaveettil R, Tomaszewski JE, Malkowicz SB: TEREI, a novel gene affecting growth regulation in prostate cancer. Prostate. 2003; 54: 144-55.
20. Xia W, Unger P, Miller L, Nelson J, Gelman IH: The Src-suppressed C kinase substrate, SseCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 2001; 61: 5644-51.
21. Nanni S, Narduci M, Pietra. LD, Moretti F, Grasselli A, De Carli O, et al.: Siganling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest. 2002; 11: 219-27.
22. Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS, et al.: A novel mechanism for Chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Research. 2001; 61: 4791-6.
23. Garcia-Fernandez MO, Solano RM, Sanchez-Chapado M, Ruiz-Villaespesa A, Prieto JC, Carmena MJ: Low expression of Galpha protein subunits in human prostate cancer. J Urol. 2001; 166: 2512-7.
24. Igawa T, Lin FF, Rao P, Lin MF: Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate. 2003; 55: 247-58.
25. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, et al.: Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol. 2001; 166: 1943-50.
26. Hering FL, Lipay MA, Rodrigues PR, Nesralah LJ, Srougi M: Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score. São Paulo Med J. 2001; 119: 138-41.
27. Nuppomen NN, Carpten JD: Prostate cancer susceptibility genes: many studies, many results, no answers. Cancer Metastasis. 2001; 20: 155-64.
28. Bratt O: Hereditary prostate cancer: clinical aspects. J Urol. 2002; 168: 906-13.
29. Kim HL, Steinberg GD: New insights and candidate genes and their implications for care of patients with hereditary prostate cancer. Curr Urol Rep. 2000; 1: 9-14.
30. Tavtigian SV, Simard J, Teng DHF, Abtin V, Baurngard M, Beck A, et al.: A candidate prostate cancer susceptibility gene at chromosome 17p. Nature Genetics. 2001; 27: 172-80.
31. De la Thille A, Olsson CA, Katz AE: Molecular staging of prostate cancer: dream or reality? Oncology. 1999; 13: 187-94.
32. Daher R, Beaini M: Prostate-specific antigen and new related markers for prostate cancer. Clin Chem Lab Med. 1998; 36: 671-81.
33. Miller, JC, Zhou H, Kweke J, Cavallo R, Burke J, Butler EB, et al.: Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers. Proteomics 2003; 3: 56-63.
34. Paweletz CP, Liotta LA, Petricoin III EF: New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology. 2001; 57 (Suppl 4A): 160-3.
35. Unwin RD, Knowles MA, Selby PJ, Banks RE: Urological malgnancies and the proteomic-genomic interface. Eletrophoresis. 1999; 20: 3629-37.
36. Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, et al.: Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis. 2000; 21: 1823-31.
37. Meehan KL, Holland JW, Dawkins HJ: Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate. 2002; 50: 54-6.
38. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al.: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62: 3609-4.
39. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al.: JAMA. 2002; 287: 1662-70.
40. Scheiermacher G, Delattre O: Détection des micrométastases et des cellules tumorales circulantes par les techniques de biologie moléculaire dans les tumeurs solides. Bull Cancer. 2001; 88: 61-70.
41. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, et al.: Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003; 55: 71-80.
42. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al.: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003; 55: 20-9.
43. Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, et al.: ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci. USA. 2001; 98: 4575-80.
44. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA: Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol. 2003; 162: 255-61.
45. Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko Sc, Kao C, et al.: Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol. 2000; 4: 73-82.
46. Mabjesh NJ, Zhong H, Simons JNV: Gene therapy of prostate cancer: current and future directions. Endocr Relat Cancer. 2002; 9: 115-39.
47. Steiner MS, Gingrich JR, Chauhan RD: Prostate cancer gene therapy. Surg Oncol Clin N Am. 2002; 11: 607-20.
48. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, et al.: Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoterdriven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003; 14: 227-41.
49. Ast G, Maul H: Drug-targeting strategies for prostate cancer. Curr Pharm Des. 2003; 9: 455-66.
50. Butler J, Rangnekar VM: Par-4 for molecular therapy of prostate cancer. Curr Drug Targets. 2003; 4: 223-30.
51. Gardner TA, Sloan J, Raikwar SP, Kao C: Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Rev. 2002; 21: 137-45.
52. Zhang L, Brereton HM, Hahn M, Froscio M, Tilley WD, Brown MP, et al.: Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Ther. 2003; 10: 611-25.
53. Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA, Buttyan R: Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy. Curr Drug Targets. 2003; 4: 191-6.
54. Collis SJ, Swartz MJ, Nelson WG, De Weese TL: Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003; 63: 1550-4.